A recombinant form of Enterococcus facieum BM4147 d-alanine-dlactate ligase (VanA) has been prepared and crystallized. VanA was found to crystallize only in the presence of a phosphinate inhibitor analogue of d-alanine-d-alanine. The crystals grow in 40±45% ammonium sulfate, 0.1 M 3-(N-morpholino)-propanesulfonic acid pH 6.0 and reach dimensions of 0.4 Â 0.2 Â 0.1 mm. The crystals diffract to at least 2.5 A Ê and are in the centred orthorhombic space group C222 1 , with unit-cell dimensions a = 123.2, b = 225.4, c = 72.4 A Ê .
Introduction
The peptidoglycan layer of bacterial cell walls is a macromolecular assembly of unusual chemical composition which provides the cell wall with its strength and rigidity and which is essential for cell viability and osmotic integrity. Peptidoglycan consists of a long alternating matrix of polysaccharide chains of N-acetylmuramic acid and N-acetylglucosamine repeats, cross-linked by short pentapeptide chains. The enzymatic cross-linking of peptidoglycan is the target for a number of important glycopeptide antibiotics such as vancomycin, the use of which is now becoming limited owing to the ever-increasing resistance mechanisms employed by various clinically important bacteria such as the Enterococci. The search for novel antibiotics and novel antibiotic targets is therefore of increasing importance, as is a greater understanding of how resistant mechanisms arise.
The structure of the pentapeptide is unusual in that it contains a number of d-amino acids. The penultimate amino acid in the peptidoglycan chain (d-alanine) crosslinks with the central amino acid in an adjacent chain. In Gram-positive bacteria, this central amino acid is l-lysine, whereas in Gram-negative bacteria this position is occupied by meso-diaminopimelate. The glycopeptide antibiotic vancomycin acts by binding to the d-alanine-dalanine termini of peptidoglycan chains, preventing crosslinking and therefore weakening the cell wall. Vancomycin-resistant organisms such as Enteroccus facieum BM4147 have become resistant by the production of peptidoglycan termini ending in a variety of alternate ester linked d-hydroxy acids such as d-lactate. A d-alanine-d-lactate depsipeptide is produced by the action of VanA from E. facieum BM4147, which has an altered af®nity from d-alanine to d-lactate at the second binding site. The resultant peptidoglycan chain has a 1000-fold decrease in vancomycinbinding af®nity which, in conjunction with the toxicity to humans of vancomycin, renders the drug unusable in patients with enterococcal infections. The gene for VanA is encoded by a transposon Tn1546 (Arthur et al., 1993) and acts in conjunction with two other genes, VanH and VanX, to produce high-level vancomycin resistance. The recently crystallized VanH (Stoll et al., 1998) is related to bacterial dlactate dehydrogenase enzymes and is responsible for the production of d-hydroxy acids. VanX is a metallodipeptidase (Wu et al., 1995) and reduces the cellular pool of dalanine-d-alanine, which would otherwise be incorporated into peptidoglycan rendering the cell susceptible to vancomycin.
The X-ray crystal structure of d-alanine-dalanine ligase (ddlB) from Escherichia coli has been solved at 2.3 A Ê resolution (Fan et al., 1994) and mutational analysis has revealed some of the key residues involved in substrate binding (Shi & Walsh, 1995; Fan et al., 1997) . Using this information, inferences have been drawn concerning the key residues in VanA thought to mediate the altered substrate speci®city crucial to the clinical importance of this enzyme. However, given that there is only 28% sequence identity between the two enzymes and the fact that VanA is some 6 kDa larger, only a full structural inspection of VanA will provide a clear description of how the substrate speci®city of this clinically important enzyme is de®ned.
Materials and methods
VanA was puri®ed from E. coli BL21(DE3) transformed with pAT214 (Dukta-Malen et al., crystallization papers 1990) using a revised protocol derived from Bugg et al. (1991) . Cells were freshly transformed and grown in Luria broth to an OD 600 of 0.5 before induction with isopropyl -d-thiogalactopyranoside to 0.5 mM. After a further 6 h of growth, ampicillin was added to 100 mg ml À1 to maintain plasmid selection prior to addition growth for 12 h. The cells were then harvested by centrifugation and stored at 193 K prior to puri®cation of the enzyme. Crude extracts were produced by sonication in 25 mM HEPES pH 8.5, 1 mM MgCl 2 , 0.1 mM EDTA. After centrifugation at 30 000g for 30 min to remove cellular debris, the bacterial cell extract was brought to 25% saturation with ammonium sulfate and precipitated proteins were removed by centrifugation. The supernatant from this step was brought to 50% saturation with ammonium sulfate to precipitate the VanA protein. The ammonium sulfate pellet was dissolved in 25 mM HEPES pH 8.5, 1 mM MgCl 2 , 0.1 mM EDTA and dialysed against the same buffer overnight at 277 K. The resulting dialysed extract was applied to a 50 ml Q-Sepharose HP column and extensively washed in the same buffer. Proteins were eluted with a linearly increasing gradient of sodium chloride to 0.5 M, with VanA eluting at approximately 100 mM NaCl. Fractions containing VanA were further puri®ed by gel ®ltration using a Superdex 75 HR26/60 column equilibrated in 50 mM HEPES pH 8.5, 1 mM MgCl 2 , 0.1 mM EDTA and 100 mM NaCl. The nonaggregated fractions were pooled and, after twofold dilution, applied to a 5 ml Q-Sepharose HP column. Proteins were eluted using a shallow gradient of NaCl to 0.3 M over 20 column volumes. Fractions containing VanA were pooled and concentrated prior to crystallization experiments. Following SDS±PAGE analysis, VanAcontaining fractions were taken and concentrated prior to crystallization. Analysis of these fractions by both SDS± PAGE and native PAGE showed them to be free of any major or minor contaminating species and the molecular mass was con®rmed by MALDI±TOF mass spectrometry.
Crystallization, data collection and processing
Crystals of VanA were grown by vapour diffusion using the hanging-drop method. Crystals were obtained in two sets of conditions from the commercially available Hampton 1 screening method (Hampton Research). Re®nement of the ammonium sulfate conditions at pHs between 6.0 and 6.5 using 0.1 M 3-(N-morpholino)-propanesulfonic acid buffer gave crystals of suf®cient quality for data collection. The protein concentration used for crystallization varied between 15 and 20 mg ml À1 in 10 mM HEPES pH 8.5, 5 mM ATP and 5 mM 1-(S)-aminoethyl [2-carboxy-2-(R)-methyl-1-ethyl] phosphinic acid phosphinate inhibitor (Ellsworth et al., 1996; Parsons et al., 1988) , using a ratio of two volumes protein to one volume of precipitant. Crystallization experiments were carried out at 290 K. For data collection, single crystals of VanA were transferred using a rayon-®bre loop into mother liquor containing glycerol, with stepwise increases in glycerol concentration from 15 to 35%. Once at 35% glycerol concentration, the loop was placed in a stream of N 2 gas at 120 K to cryo-cool the crystal. Data were collected with an oscillation range of 1 per image using a Cu K radiation source and a MAR Research MAR345 image-plate device. The data were processed and reduced using the HKL suite of programs (Otwinowski & Minor, 1997) .
Results and discussion
Attempts to overexpress the protein in a T7 promoter-based system using a polyhistidine tag for rapid af®nity puri®cation were successful, but for unknown reasons did not yield protein that would crystallize. Expression of VanA using a constitutive expression system achieved a yield of approximately 10±20% of total soluble protein after overnight induction. The recombinant protein was puri®ed using a modi®ed protocol to that published (Bugg et al., 1991) to above 99% purity as judged by SDS. Puri®cation of the enzyme is shown in Fig. 1 . The protein was found to be unstable at neutral pH, in addition to lowsalt conditions as previously described by Bugg et al. (1991) . By maintaining the protein at an alkaline pH of 8.5, we were able to minimize aggregation, which had proved to be a serious problem in early preparations of VanA. The aggregation state of the protein was monitored throughout the puri®cation using native gel electrophoresis. It was also our experience that VanA either precipitated or bound irreversibly to highresolution ion-exchange media including Mono-Q, Resource-Q and Source-Q media, which hampered the production of protein samples of suf®cient purity for crystallization. The subunit molecular weight of the protein was determined by MALDI±TOF MS as 37 499 Da, compared with a calculated molecular weight of 37 419 Da. Crystals of VanA appear within 5±7 d at 290 K in the presence of ATP and d-alanined-alanine phosphinate inhibitor (see Fig. 2 ) and were of a size suitable for X-ray data collection. The crystals are of space group C222 1 , with unit-cell dimensions a = 123.2, b = 225.36, c = 72.44 A Ê . Using the method of Matthews (1968) , the solvent content of these crystals was calculated to be 63.13%, with a Matthews coef®cient of 3.36 A Ê Da À1 , assuming two molecules in the asymmetric unit. X-ray diffraction data to 2.5 A Ê resolution (values for the outer resolution shell, 2.54±2.50 A Ê , are given in parentheses) are complete to 93.3% overall (96.6%) with an R merge of 5.8% (21.7%), a multiplicity of 4.23 (3.85) observations per re¯ection and a mean I/'(I) of 29.9 (4.1).
A structure for VanA will further elucidate the molecular events leading to peptidoglycan biosynthesis in the clinically relevant Enterococci and shed further light 
Figure 2
Photograph of VanA crystal of approximate dimensions 0.5 Â 0.2 Â 0.1 mm. crystallization papers on possible mechanisms and targets for novel antibacterial agents.
